PTO/SB/05 (08-00)

39,395

Date 12-28-2000

Registration No. (Attorney/Agent)

Please type a plus sign (+) inside this box -



Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.		1242/27/2/2				
First Inventor		David Robertson				
Title	See 1 in	Addendum.				

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. EK580268962US Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or X Computer Program (Appendix) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission 2. **X** See 37 CFR 1.27. (if applicable, all necessary) specification [Total Pages **148**] (preferred arrangement set forth below) a. X Computer Readable Form (CRF) 3. **X** - Descriptive title of the invention Specification Sequence Listing on: - Cross Reference to Related Applications i. CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, ii. 🖺 paper or a computer program listing appendix c. X Statements verifying identity of above copies - Background of the Invention Brief Summary of the Invention
Brief Description of the Drawings (if filed) ACCOMPANYING APPLICATION PARTS Assignment Papers (cover sheet & document(s)) - Detailed Description 9. Power of 37 CFR 3.73(b) Statement - Abstract of the Disclosure (when there is an assignee) Attorney English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets 4] 4. X Copies of IDS Information Disclosure 5. Oath or Declaration [Total Pages 2] Citations Statement (IDS)/PTO-1449 13 Preliminary Amendment Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 17 compléted) 14. 🗙 (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** 15. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 16. 1.63(d)(2) and 1 33(b) Application Data Sheet. See 37 CFR 1.76 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: of prior application No .__ Continuation Divisional Continuation-in-part (CIP) Prior application information For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 18. CORRESPONDENCE ADDRESS Correspondence address below Customer Number or Bar Code Label Name Address Zip Code State City Fax Telephone Country

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Arles A. Taylor, Jr.

Name (Print/Type)

Signature

Attachment to PTO/SB/05 (08/00) Utility Patent Application Transmittal

1. GENETIC MUTATION UNDERLYING ORTHOSTATIC INTOLERANCE AND DIAGNOSTIC AND THERAPEUTIC METHODS RELATING THERETO

PTO/SB/17 (11-00)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to re

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT

(\$) **1,319.00**

spond to a conection or mic	illiation unless it displays a valid Civip Condict House	×				
Complete if Known						
Application Number						
Filing Date						
First Named Inventor	David Robertson					
Examiner Name						
Group Art Unit						
Attorney Docket No.	1242/27/2/2					

METHOD OF PAYMENT	FEE CALCULATION (continued)					
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES					
Indicated lees and credit any overpayments to:	Large	Smal	II			
Deposit Account	Entity Fee Fee Fee	Entit	•	Fee Paid		
Number	Fee Fee Fee Code (\$) Code		Fee Description	ree raiu		
Deposit Account Name	105 130 205	65	Surcharge - late filing fee or oath			
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17	127 50 227	25	Surcharge - late provisional filing fee or cover sheet			
Applicant claims small entity status.	139 130 139	130	Non-English specification			
See 37 CFR 127	147 2,520 147	2,520	For filing a request for ex parte reexamination			
2. Payment Enclosed: Check Credit card Money Other	112 920* 112	920*	Requesting publication of SIR prior to Examiner action			
Check Credit card Order Other	113 1,840* 113	1,840*	Requesting publication of SIR after Examiner action			
	115 110 215	55	Extension for reply within first month			
1. BASIC FILING FEE Large Entity Small Entity	116 390 216	195	Extension for reply within second month			
Fee Fee Fee Fee Description	117 890 217	445	Extension for reply within third month			
Code (4)	118 1,390 218	695	Extension for reply within fourth month			
	128 1,890 228	945	Extension for reply within fifth month			
106 320 206 160 Design filing fee 107 490 207 245 Plant filing fee	119 310 219	155	Notice of Appeal			
108 710 208 355 Reissue filing fee	120 310 220	155	Filing a brief in support of an appeal			
114 150 214 75 Provisional filing fee	121 270 221	135	Request for oral hearing			
	138 1,510 138	1,510	Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 355.00	140 110 240	55	Petition to revive - unavoidable			
2. EXTRA CLAIM FEES Fee from	141 1,240 241	620	Petition to revive - unintentional			
Extra Claims below Fee Paid	142 1,240 242	620	Utility issue fee (or reissue)			
Total Claims 81 -20** = 61 X 9 = 549	143 440 243	220	Design issue fee			
Independent	144 600 244	300	Plant issue fee			
Multiple Dependent 135 = 135	122 130 122	130	Petitions to the Commissioner			
	123 50 123	50	Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity Fee Fee Fee Fee Fee Description	126 180 126	180	Submission of Information Disclosure Stmt			
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581	40	Recording each patent assignment per property (times number of properties)			
102 80 202 40 Independent claims in excess of 3	146 710 246	355	Filing a submission after final rejection			
104 270 204 135 Multiple dependent claim, if not paid	240		(37 CFR § 1 129(a))			
109 80 209 40 ** Reissue independent claims over original patent	149 710 249	355	For each additional invention to be examined (37 CFR § 1.129(b))			
110 18 210 9 ** Reissue claims in excess of 20	179 710 279	355	Request for Continued Examination (RCE)			
and over original patent	169 900 169	900	Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 964.00	Other fee (specify)					
**or number previously paid, if greater, For Reissues, see above	*Reduced by Basi	ic Filing	Fee Paid SUBTOTAL (3) (\$) 0.0	00		

SUBMITTED BY				Complete (if applicable)	
Name (Print/Type)		Registration No. (Attorney/Agent) 39,395	Telephone	(919)493-8000	
Signature	Only a. Layer, J.		Date	12-28-2000	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.